Molecular Partners AG
MOLN
株式のランク
#19719
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
株価
$3.70
時価総額
$141.78M
変化（1日）
0.33%
変化（1年）
3.73%
国
CH
取引 Molecular Partners AG (MOLN)
カテゴリー
Healthcare
Molecular Partners AG（MOLN）の収益
Oct 2026 時点の収益 TTM: 0
Molecular Partners AG の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Molecular Partners AG の収益履歴（2013 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2025 | 0.00 | -100.00% |
| 2024 | $5.50M | -34.25% |
| 2023 | $8.37M | -95.92% |
| 2022 | $205.08M | 1,816.85% |
| 2021 | $10.70M | 2.85% |
| 2020 | $10.40M | -50.63% |
| 2019 | $21.07M | 100.17% |
| 2018 | $10.53M | -48.75% |
| 2017 | $20.54M | -9.28% |
| 2016 | $22.64M | -22.29% |
| 2015 | $29.13M | 8.69% |
| 2014 | $26.80M | -26.22% |
| 2013 | $36.33M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
